A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting
Abstract This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID + microarray, we evaluated IgG-S and...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-05377-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238611742949376 |
|---|---|
| author | Aini Syahida Mat Yassim Anis Atifah Mohd Hisham Nik Nur Atiqah Nik Daud Nur Diana Anuar Ti-Myen Tan Rapeah Suppian Mat Jusoh Siti Asmaa Amiratul Aifa Mohamad Asri Maryam Azlan Nur Suhaila Idris Rosediani Muhamad Mohd Nor Norazmi |
| author_facet | Aini Syahida Mat Yassim Anis Atifah Mohd Hisham Nik Nur Atiqah Nik Daud Nur Diana Anuar Ti-Myen Tan Rapeah Suppian Mat Jusoh Siti Asmaa Amiratul Aifa Mohamad Asri Maryam Azlan Nur Suhaila Idris Rosediani Muhamad Mohd Nor Norazmi |
| author_sort | Aini Syahida Mat Yassim |
| collection | DOAJ |
| description | Abstract This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID + microarray, we evaluated IgG-S and NAb against Wuhan-Hu and VoCs (Alpha, Beta, Delta, Omicron), as well as IgG-N responses to Wuhan-Hu. BNT162b2 induced higher IgG-S levels and seropositivity than CoronaVac after primary immunization. While a heterologous CoronaVac-BNT162b2 temporarily increased IgG-S levels, long-term IgG-S levels and seropositivity remained comparable between the two groups across all variants. NAb levels were higher in BNT162b2 recipients than in CoronaVac recipients, with homologous BNT162b2 boosters sustaining higher NAb levels for Wuhan-Hu compared to heterologous BNT162b2-CoronaVac. However, responses to other variants varied. Expectedly, CoronaVac uniquely induced IgG-N responses, resulting in elevated IgG-N levels in heterologous BNT162b2-CoronaVac recipients compared to homologous BNT162b2 recipients. Overall, BNT162b2 boosters conferred robust and durable antibody responses regardless of the primary vaccine used. Higher IgG-N levels prior to immunization, compared to pre-pandemic levels, suggest that prior exposure to circulating SARS-CoV-2 VoCs (other than Wuhan-Hu) in Malaysia shaped immune imprinting, influencing responses before immunization with the Wuhan-Hu-based vaccine. Consequently, this study reports higher IgG-S and NAb levels against VoCs—except Omicron—compared to Wuhan-Hu after COVID-19 vaccination. |
| format | Article |
| id | doaj-art-4e614a6b33c84d8cba74d0f734526523 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-4e614a6b33c84d8cba74d0f7345265232025-08-20T04:01:34ZengNature PortfolioScientific Reports2045-23222025-07-0115112610.1038/s41598-025-05377-3A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boostingAini Syahida Mat Yassim0Anis Atifah Mohd Hisham1Nik Nur Atiqah Nik Daud2Nur Diana Anuar3Ti-Myen Tan4Rapeah Suppian5Mat Jusoh Siti Asmaa6Amiratul Aifa Mohamad Asri7Maryam Azlan8Nur Suhaila Idris9Rosediani Muhamad10Mohd Nor Norazmi11School of Health Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaSengenics CorporationSengenics CorporationSchool of Health Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaSchool of Medical Sciences, Universiti Sains MalaysiaSchool of Medical Sciences, Universiti Sains MalaysiaSchool of Health Sciences, Universiti Sains MalaysiaAbstract This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID + microarray, we evaluated IgG-S and NAb against Wuhan-Hu and VoCs (Alpha, Beta, Delta, Omicron), as well as IgG-N responses to Wuhan-Hu. BNT162b2 induced higher IgG-S levels and seropositivity than CoronaVac after primary immunization. While a heterologous CoronaVac-BNT162b2 temporarily increased IgG-S levels, long-term IgG-S levels and seropositivity remained comparable between the two groups across all variants. NAb levels were higher in BNT162b2 recipients than in CoronaVac recipients, with homologous BNT162b2 boosters sustaining higher NAb levels for Wuhan-Hu compared to heterologous BNT162b2-CoronaVac. However, responses to other variants varied. Expectedly, CoronaVac uniquely induced IgG-N responses, resulting in elevated IgG-N levels in heterologous BNT162b2-CoronaVac recipients compared to homologous BNT162b2 recipients. Overall, BNT162b2 boosters conferred robust and durable antibody responses regardless of the primary vaccine used. Higher IgG-N levels prior to immunization, compared to pre-pandemic levels, suggest that prior exposure to circulating SARS-CoV-2 VoCs (other than Wuhan-Hu) in Malaysia shaped immune imprinting, influencing responses before immunization with the Wuhan-Hu-based vaccine. Consequently, this study reports higher IgG-S and NAb levels against VoCs—except Omicron—compared to Wuhan-Hu after COVID-19 vaccination.https://doi.org/10.1038/s41598-025-05377-3BNT162b2CoronaVacHomologous and heterologous boosterNeutralizing antibodiesIgG-S and IgG-N antibodiesVariants of concern |
| spellingShingle | Aini Syahida Mat Yassim Anis Atifah Mohd Hisham Nik Nur Atiqah Nik Daud Nur Diana Anuar Ti-Myen Tan Rapeah Suppian Mat Jusoh Siti Asmaa Amiratul Aifa Mohamad Asri Maryam Azlan Nur Suhaila Idris Rosediani Muhamad Mohd Nor Norazmi A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting Scientific Reports BNT162b2 CoronaVac Homologous and heterologous booster Neutralizing antibodies IgG-S and IgG-N antibodies Variants of concern |
| title | A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting |
| title_full | A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting |
| title_fullStr | A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting |
| title_full_unstemmed | A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting |
| title_short | A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting |
| title_sort | 22 month prospective assessment of neutralizing and igg antibody levels against sars cov 2 variants following homologous and heterologous bnt162b2 boosting |
| topic | BNT162b2 CoronaVac Homologous and heterologous booster Neutralizing antibodies IgG-S and IgG-N antibodies Variants of concern |
| url | https://doi.org/10.1038/s41598-025-05377-3 |
| work_keys_str_mv | AT ainisyahidamatyassim a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT anisatifahmohdhisham a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT niknuratiqahnikdaud a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT nurdianaanuar a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT timyentan a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT rapeahsuppian a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT matjusohsitiasmaa a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT amiratulaifamohamadasri a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT maryamazlan a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT nursuhailaidris a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT rosedianimuhamad a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT mohdnornorazmi a22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT ainisyahidamatyassim 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT anisatifahmohdhisham 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT niknuratiqahnikdaud 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT nurdianaanuar 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT timyentan 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT rapeahsuppian 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT matjusohsitiasmaa 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT amiratulaifamohamadasri 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT maryamazlan 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT nursuhailaidris 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT rosedianimuhamad 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting AT mohdnornorazmi 22monthprospectiveassessmentofneutralizingandiggantibodylevelsagainstsarscov2variantsfollowinghomologousandheterologousbnt162b2boosting |